GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (STU:2MT0) » Definitions » Issuance of Debt

Athenex (STU:2MT0) Issuance of Debt : €77.20 Mil (TTM As of Dec. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Athenex Issuance of Debt?

Athenex's Issuance of Debt for the three months ended in Dec. 2022 was €0.00 Mil.

Athenex's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2022 was €77.20 Mil.


Athenex Issuance of Debt Historical Data

The historical data trend for Athenex's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex Issuance of Debt Chart

Athenex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Issuance of Debt
Get a 7-Day Free Trial 43.95 5.82 119.29 - 76.94

Athenex Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 75.68 1.52 -

Athenex Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €77.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Athenex Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Athenex's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Athenex Business Description

Traded in Other Exchanges
N/A
Address
1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Athenex Headlines

No Headlines